Denileukin Diftitox: a Concise Clinical Review

Overview

Journal Expert Rev Anticancer Ther

Specialties Oncology
Pharmacology

Date 2005 Mar 11

PMID 15757436

Citations 17

Authors

John W Eklund

Timothy M Kuzel

Affiliations

Soon will be listed here.

Abstract

Denileukin diftitox (DAB389IL-2; Ontak) is a novel recombinant fusion protein approved by the US Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma. It consists of fragments of diphtheria toxin linked to human interleukin-2 and works by targeting the high-affinity interleukin-2 receptor expressed on malignant cells. This article will review the clinical trials leading to the approval of denileukin diftitox for cutaneous T-cell lymphoma, and discuss the potential future role of this novel drug in patients with both malignant and nonmalignant diseases, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, solid tumors, psoriasis and graft-versus-host disease.

Citing Articles

Cancer Drug Delivery Systems Using Bacterial Toxin Translocation Mechanisms.

Yin L, Thaker H Bioengineering (Basel). 2023; 10(7).

PMID: 37508840 PMC: 10376142. DOI: 10.3390/bioengineering10070813.

Interleukin 2-Based Fusion Proteins for the Treatment of Cancer.

MacDonald A, Wu T, Hung C J Immunol Res. 2021; 2021:7855808.

PMID: 34790830 PMC: 8592747. DOI: 10.1155/2021/7855808.

A Single-Domain Antibody-Based Anti-PSMA Recombinant Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Therapy.

Xing Y, Xu K, Li S, Cao L, Nan Y, Li Q Int J Mol Sci. 2021; 22(11).

PMID: 34071152 PMC: 8197099. DOI: 10.3390/ijms22115501.

Effective Host-Directed Therapy for Tuberculosis by Depletion of Myeloid-Derived Suppressor Cells and Related Cells Using a Diphtheria Toxin Fusion Protein.

Parveen S, Lun S, Urbanowski M, Cardin M, Shen J, Murphy J J Infect Dis. 2021; 224(11):1962-1972.

PMID: 33955457 PMC: 8643419. DOI: 10.1093/infdis/jiab235.

Immunogenicity of Immunotoxins Containing Exotoxin A: Causes, Consequences, and Mitigation.

Mazor R, Pastan I Front Immunol. 2020; 11:1261.

PMID: 32695104 PMC: 7333791. DOI: 10.3389/fimmu.2020.01261.